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ABSTRACT
INTRODUCTION
Bleeding can cause significant morbidity and 
mortality in clinical settings. Several haemostatic 
agents have been investigated for their role in 
haemostasis6,9,11,13.
Ankaferd Blood Stopper® (ABS; Ankaferd Health 
Products Ltd., Istanbul, Turkey) is a traditional 
folk medicinal plant extract product that has 
been approved in the management of external 
hemorrhage and dental surgery bleedings in 
Turkey. ABS comprises a standardized mixture of 
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Objective: Several haemostatic agents are available for clinical use. Ankaferd Blood 
Stopper® (ABS), a mixture of five medicinal plant extracts, has been used historically as 
a haemostatic agent. The aim of this in vivo study was to investigate the effects of ABS 
on early bone healing using a rat tibia defect model. Material and Methods: Sixteen male 
Wistar rats were randomized into two groups of 8 animals each. After deep anesthesia 
with ketamine, bone defects (3 mm diameter and 2 mm deep) were created in the right 
and left tibiae of all animals and either treated with 1 cc of ABS (Group 1) or left untreated 
(Group 2; control). Surgical areas were closed primarily. The animals were sacrificed on 
the 7th postoperative day and bone samples were collected from the tibias. The samples 
were examined histopathologically for infection, necrosis, fibrosis, new bone formation and 
foreign body reaction. The histomorphometric results were analyzed statistically by the chi 
square test, with the level of significance set at p<0.05. Results: Significant differences 
were found in both groups in terms of inflammation, necrosis and new bone formation 
(p=0.001, p=0.0001, p=0.001). No foreign body reaction was observed in the experimental 
group. ABS application decreased fibrosis in the experimental group, but there were no 
statistically significant differences from the control group. Conclusions: Histopathologically, 
it was observed that the application of ABS decreased the occurrence of inflammation and 
necrosis, while increasing new bone formation in early bone healing period. Further in vitro 
and in vivo studies are necessary for evaluating the benefits and possible adverse effects 
of the application of this herbal product on wound healing.
Key words: Ankaferd Blood Stopper® (ABS). Thymus vulgaris. Glycyrrhiza glabra. Vitis 
vinifera. Alpinia officinarum. Urtica dioica. Herbal medicines. Bone healing.
the plants Thymus vulgaris, Glycyrrhiza glabra, 
Vitis vinifera, Alpinia officinarum and Urtica dioica. 
Several studies have shown that each of these 
plants has some effect on the endothelium, blood 
cells, angiogenesis, cellular proliferation, vascular 
dynamics and cell mediators2,3,7,8,10,12. Göoker, et al.5 
(2008) investigated the haemostatic effects of ABS 
and reported its therapeutic potential to be used 
for the management of haemorrhage5.
Although clinical and in vivo studies have been 
reported about different haemostatic agents that are 
commonly used for the management of hemorrhage 
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in clinical dentistry6,13, there is no evidence about 
the effects of ABS in vivo experimental models. 
The aim of this in vivo study was to investigate the 
effects of Ankaferd Blood Stopper® on early bone 
healing using a rat tibia defect model.
MATERIAL AND METhODS
Animals and Surgery
The study was carried out in the Istanbul 
University, Faculty of Dentistry, Department 
of Oral & Maxillofacial Surgery and Institute of 
Oncology, Department of Tumor Pathology & 
Cytology. Treatment of the experimental animals 
was approved by the Istanbul University Animal 
Research and ethics Committee. experimental 
animals were obtained from The Laboratory of 
experimental Animals, DeTAM, Istanbul, Turkey.
A total of 16 twenty-week-old male Wistar rats 
weighing 250 to 300 g were used in this study and 
randomly assigned to two groups of 8 animals each. 
Prior to surgery, the animals were anesthetized with 
a 0.7 mL intramuscularly injection of a solution 
containing xylazine hydrochloride (Rompun®, Bayer, 
Leverkusen, Germany) and ketamine hydrochloride 
(Ketalar; Pfizer, New York, NY USA) at 1/0.5 
proportion, 0.1 mL/100 g body weight. Surgery 
was performed under sterile conditions.
In the mid tibia of rats, a 5-mm long straight 
longitudinal skin incision was done on the front skin 
and, after muscle splitting (plane-by-plane muscle 
dissection), the periosteal membrane was stripped 
away to expose bone surface. A standardized 
ellipsoid round bone defect (5 mm in length, 1 
mm in height, 1 mm in depth) was created at the 
anterior portion of the diaphysis of bilateral tibias, 6 
mm below the knee joint using a round carbide bur 
(SS White, Lakewood, NJ, USA). The defect size was 
confirmed by a surgical stainless steel stent with 
the corresponding dimensions. The surgical stent 
was placed in the defect and confirmed visually by 
checking congruity to the defect wall.
Group 1 received 1 cc of Ankaferd Blood 
Stopper® at the time of surgery, while Group 2 
received no treatment and served as the control. 
The muscles were sutured with 4/0 catgut (Doğsan, 
Istanbul, Turkey), and the flaps were carefully 
repositioned and sutured with 3/0 black silk sutures 
(Doğsan, Istanbul, Turkey). Antibiotic (Sefazol, 
Mustafa Nevzat, Turkey) was given to the animals 
as an intramuscular injection intraoperatively and 
during 3 days postoperatively. No postoperative 
complications were noticed during the postsurgical 
course. All animals survived throughout the study 
period.
The rats of each group were housed into 
separate cages with two or three animals under 
climate-controlled conditions (12 h light/12 h dark; 
thermostatically regulated room temperature) 
without any restriction of mobilization. The animals 
of each group were sacrificed with an overdose 
of ketamine hydrochloride (50 mg/kg) on the 7th 
day after surgery, and the defects together with 
surrounding bone were immediately removed for 
histopathological analysis.
Tissue Preparation and histopathological 
Examination
The specimens were fixed in 10% neutral 
buffered formalin overnight at 4°C, rinsed in 
phosphate buffered saline and decalcified in 20% 
formic acid solution (Merck, Darmstadt, Germany) 
for 10 days. The decalcified specimens were 
embedded in paraffin and cut into 20 semi-serial 
sections using a microtome (Leica Microsystemic, 
Germany), and routine hematoxylin and eosin 
(He) staining and Mallory Trichrome staining were 
performed. The sections were examined with light 
microscope under 40, 100 and 200x magnification 
(Nikon eclipse e600, Japan). A histomorphological 
review was performed by a single blinded oral 
pathologist to evaluate the presence of infection, 
necrosis, fibrosis, new bone formation, and foreign 
body reaction. The scores for infection, necrosis, 
fibrosis and new bone formation scores were 
determined by counting the associated cells and 
their ratio to the total cell count in a standardized 
area at 40x magnification. The ratio of cells between 
0-25% was scored as none, 25-50% as slight, 50-
75% as moderate, and 75-100% as advanced.
Statistical analysis
The statistical differences between the control 
and test groups were compared by chi square test 
using the GraphPad Prisma V.3 (GraphPad Software, 
Inc., USA) and the critical level of significance was 
P < 0.05.
RESULTS
The scores and percentages of inflammation, 
necrosis, fibrosis, and new bone formation in both 
groups are presented in Table 1 and illustrated in 
Figures 1 and 2. Comparisons between the test 
and control groups indicate a significant variability 
in the scores of inflammation, necrosis and new 
bone formation (p<0.001, p<0.0001, p<0.001, 
respectively). No foreign body reactions were seen 
in either of the groups.
In the control group, 62.5% and 37.5% of 
the specimens showed slight and moderate 
inflammation, respectively. In the test group, 36.4% 
of the specimens showed slight inflammation, 
while 63.6% of them were free of inflammation. 
Statistically significant differences (p<0.001) were 
found between the test and control groups.
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There was statistically significant difference 
between the groups as for the necrosis scores 
(p<0.0001). In the test group, 90.9% of the 
specimens did not show necrosis, while in the 
control group slight, moderate and advanced 
necrosis was observed in 6.3%, 87.5% and 6.3% 
of the specimens, respectively.
Both groups showed similar range of fibrosis 
scores with no statistically significant difference 
(p= 0.171) between them.
Table 1- Inflammation, necrosis, fibrosis and bone formation scores in the test and control groups
Inflammation % n % n
None 63.6 7 0.0 0
Slight 36.4 4 62.5 10
Moderate 0.0 0 37.5 6
Advanced 0.0 0 0.0 0
χ²:15.16 p=0.001
Necrosis % n % n
None 90.9 10 0.0 0
Slight 9.1 1 6.3 1
Moderate 0.0 0 87.5 14
Advanced 0.0 0 6.3 1
χ²:24.92 p=0.0001
Fibrosis % n % n
None 9.1 1 0.0 0
Slight 27.3 3 62.5 10
Moderate 54.5 6 37.5 6
Advanced 9.1 1 0.0 0
χ²:5.01 p=0.171
Bone formation % n % n
None 0.0 0 31.3 5
Slight 18.2 2 68.8 11
Moderate 45.5 5 0.0 0
Advanced 36.4 4 0.0 0
χ²:19.99 p=0.0001
Control groupTest group
Control groupTest group
Control groupTest group
Control groupTest group
Figure 1- Comparison of inflammation, necrosis, fibrosis and bone formation scores in test group in percentage
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The results showed that bone formation scores 
were significantly higher in the test group than in 
the control group (p<0.0001). In the group treated 
with ABS, slight, moderate and advanced bone 
formation was observed in 18.2%, 45.5% and 
36.4% of the specimens, respectively.
Representative histological sections of various 
specimens in the test group that showed decreased 
inflammation and necrosis, and increased new bone 
formation in early bone healing period are illustrated 
in Figures 3 and 4.
Figure 2- Comparison of inflammation, necrosis, fibrosis and bone formation scores in control group in percentage
Figure 3- (a) Non-remodeled newly formed bone tissue covering the defect area and filling the medullar space (Hematoxylin-
Eosin (HE) x40). (b) Numerous new bone trabeculae in vessel-rich loose connective tissue at the medullar space (H&E 
x200). (c) New bone trabeculae surrounding an organizing hematoma (HE x100). (d) New bone formation areas and mild 
lymphocyte infiltration in an active fibrous tissue formed by mesenchymal cells (HE x200)
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DISCUSSION
Bleeding can cause significant morbidity 
and mortality in any clinical setting. Bleeding 
management has been studied extensively and 
various haemostatic agents are available for clinical 
use6,13.
ABS is a folkloric medicinal plant extract 
product, which has historically been used in 
Turkish traditional medicine as a haemostatic 
agent. It is a standardized mixture of the plants 
T. vulgaris, G. glabra, V. vinifera, A. officinarum 
and U. dioica, each of which has some effect 
on hematological and vascular parameters, and 
cellular proliferation2,3,7,8,10,12. each ingredient 
of this mixture has specific characteristics. G. 
glabra inhibits angiogenesis, decreases vascular 
endothelial growth factor production and cytokine-
induced neovascularization. G. glabra also has 
antiinflammatory, anti-thrombin, antiplatelet, 
antioxidant, anti-atherosclerotic, and antitumor 
activities10. T. vulgaris has been shown to exhibit 
varying levels of anti-oxidant activity, which 
may help to prevent in vivo oxidative damage, 
such as lipid peroxidation, associated with 
atherosclerosis7. Inoculation experiments on 
detached leaves of V. vinifera exhibited enhanced 
resistance towards pathogens2,3. V. vinifera also 
has anti-atherosclerotic and antitumor effects14,15. 
A. officinarum inhibits nitric oxide production in 
lipopolysaccharide activated mouse peritoneal 
macrophages8. U. dioica can produce hypotensive 
responses through a vasorelaxation effect mediated 
by the release of endothelial nitric oxide and the 
opening of potassium channels, and through a 
negative inotropic action12.
Goker, et al.5 (2008) showed that the ABS-
induced network formation is related to the 
functions of blood proteins and red blood cells. 
The basic mechanism of action for ABS appears 
to be the formation of an encapsulated protein 
network that provides focal points for erythrocyte 
aggregation. Blood cells (erythrocytes and 
platelets) also aggregated and participated in the 
network formation, with the erythrocytes forming 
a mass. exposure to ABS seems to provide a tissue 
oxygenation as well as a physiological haemostatic 
process without affecting any individual clotting 
Figure 4- (a) New bone tissue layer separated from the defect wall by apposition lines, which is located in the loose connective 
tissue with mild inflammatory cell infiltration at the apex of the defect fragment (Hematoxylin-Eosin (HE) x200). (b) Areas 
of endochondral ossification in an active connective tissue at the defect area (HE x200). (c) Subperiostal ossification and 
osteoprogenitor cells that are proliferated and transforming into osteoblasts underneath the periosteum, which is traumatized 
near the defect area (HE x200). (d) Vessel-rich active connective tissue formed by fusiform cells underneath the surface 
epithelium (HE x200).
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factor. This unique mechanism of action provides 
ABS with an advantage over other haemostatically 
active plant extracts1,4.
The histopathological results of the present 
study showed that over sixty percent of the defects 
treated with ABS were free of inflammation, which 
is probably related to the antiinflammatory activity 
of some components of the haemostatic agent. 
Although the occurrence of fibrosis was statistically 
similar in both groups, the ABS-treated group 
showed lower fibrosis rate than the non-treated 
control group, which may be attributed to the 
increased speed of healing in the test group.
The defects treated with ABS also showed more 
intense new bone formation and less occurrence 
of necrosis, which may be related to the increased 
speed of healing and decreased inflammation 
which is associated with antioxidant activity of the 
components of the ABS.
CONCLUSION
Within the limitations of this study, the following 
conclusions were drawn: 1. ABS decreased 
the inflammation and necrosis process; 2. ABS 
increased the new bone formation in early bone 
healing period; 3. No foreign body reaction to ABS 
was observed; 4. Further in vitro and in vivo studies 
are necessary to assess benefits and possible 
adverse effects of the application of Ankaferd Blood 
Stopper® on wound healing.
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